Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms
pharmaceutical investing Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing
pharmaceutical investing 1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations
pharmaceutical investing Sorrento Acquires the Sofusa Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics
Apex Extends Trinity Zone 200 m with 3.55% REO over 116.0 m and 2.35% over 171.5 m in Western Step-out Drilling at Rift
Goldera Expands High-Grade E1 Gold Discovery with Two New Parallel Structures Ahead of Planned Q4 Drilling at Egan Gold Project
Oreterra CEO Letter to Shareholders Provides Forward Guidance on Trek South Drill Results in Advance of Assays
